Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination

Journal of Dermatological Science

Volumn 54, Issue 1, 2009, Pages 31-37

  Nakai, Noriaki ^a   Katoh, Norito ^a   Kitagawa, Tomoko ^a   Ueda, Eiichiro ^a   Takenaka, Hideya ^a   Kishimoto, Saburo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Dendritic cells vaccination; Forkhead box protein 3; Melanoma; Regulatory T cells

Indexed keywords

DENDRITIC CELL VACCINE; FORKHEAD TRANSCRIPTION FACTOR; FORKHEAD TRANSCRIPTION FACTOR 3; MELANOMA ANTIGEN; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MELANOMA; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MALE; MELANOMA; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; SKIN NEOPLASMS; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; VACCINATION;

EID: 60749108869     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2008.11.007     Document Type: Article

References (28)

1. Ishihara K., Saida T., Yamamoto A., and Otsuka F. Nationwide survey of malignant skin tumors (1997-2001). Skin Cancer (Japan) 19 (2004) 147-155
2. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4 (1998) 328-332
3. Nakai N., Asai J., Ueda E., Takenaka H., Katoh N., and Kishimoto S. Vaccination of Japanese patients with advanced melanoma with peptide, tumor lysate or both peptide and tumor lysate-pulsed mature, monocyte-derived dendritic cells. J Dermatol 33 (2006) 462-472
4. Tuettenberg A., Schmitt E., Knop J., and Jonuleit H. Dendritic cell-based immunotherapy of malignant melanoma: success and limitations. J Dtsch Dermatol Ges 5 (2007) 190-196
5. Mazda O., and Germeraad W.T.V. Tumor immunity and immuno-gene therapy of malignancies. In: Mazda O. (Ed). Frontiers in immuno-gene therapy (2004), Research Signpost, Trivandrum 1-30
6. Berger T.G., Haendle I., Schrama D., Luftl M., Bauer N., Pedersen L.O., et al. Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells. Int J Cancer 111 (2004) 229-237
7. Nakai N., Katoh N., Germeraad W.T., Kishida T., Ueda E., Takenaka H., et al. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination. J Dermatol Sci 53 (2009) 40-47
8. Nakai N., Katoh N., Kitagawa T., Ueda E., Takenaka H., and Kishimoto S. Evaluation of survival in Japanese stage IV melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cells. J Dermatol 35 (2008) 801-803
9. Banerjee D.K., Dhodapkar M.V., Matayeva E., Steinman R.M., and Dhodapkar K.M. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 108 (2006) 2655-2661
10. Ahmadzadeh M., and Rosenberg S.A. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107 (2006) 2409-2414
11. Hori S., and Sakaguchi S. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect 6 (2004) 745-751
12. Wang R.F., Miyahara Y., and Wang H.Y. Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 27 (2008) 181-189
13. Mittal S., Marshall N.A., Duncan L., Culligan D.J., Barker R.N., and Vickers M.A. Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood 111 (2008) 5359-5370
14. Liu L., Wu G., Yao J.X., Ding Q., and Huang S.A. CD4+CD25 high regulatory cells in peripheral blood of cancer patients. Neuro Endocrinol Lett 29 (2008) 240-245
15. Liyanage U.K., Moore T.T., Joo H.G., Tanaka Y., Herrmann V., Doherty G., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169 (2002) 2756-2761
16. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004) 942-949
17. Yamazaki S., Iyoda T., Tarbell K., Olson K., Velinzon K., Inaba K., et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 198 (2003) 235-247
18. Yamazaki S., Patel M., Harper A., Bonito A., Fukuyama H., Pack M., et al. Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc Natl Acad Sci USA 103 (2006) 2758-2763
19. Abe M., Uchihashi K., Kazuto T., Osaka A., Yanagihara K., Tsukasaki K., et al. Foxp3 expression on normal and leukemic CD4+CD25+ T cells implicated in human T-cell leukemia virus type-1 is inconsistent with Treg cells. Eur J Haematol 81 (2008) 209-217
20. Xu D., Fu J., Jin L., Zhang H., Zhou C., Zou Z., et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 177 (2006) 739-747
21. Beyer M., and Schultze J.L. Regulatory T cells in cancer. Blood 108 (2006) 804-811
22. Slingluff Jr. C.L., Engelhard V.H., and Ferrone S. Peptide and dendritic cell vaccines. Clin Cancer Res 12 (2006) 2342s-2345s
23. Begley J., and Ribas A. Targeted therapies to improve tumor immunotherapy. Clin Cancer Res 14 (2008) 4385-4391
24. Lizee G., Radvanyi L.G., Overwijk W.W., and Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res 12 (2006) 4794-4803
25. Liu J.Y., Wu Y., Zhang X.S., Yang J.L., Li H.L., Mao Y.Q., et al. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother 56 (2007) 1597-1604
26. Hegde U., Chhabra A., Chattopadhyay S., Das R., Ray S., and Chakraborty N.G. Presence of low dose of fludarabine in cultures blocks regulatory T cell expansion and maintains tumor-specific cytotoxic T lymphocyte activity generated with peripheral blood lymphocytes. Pathobiology 75 (2008) 200-208
27. Matsushita N., Pilon-Thomas S.A., Martin L.M., and Riker A.I. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 333 (2008) 167-179
28. Jarnicki A.G., Conroy H., Brereton C., Donnelly G., Toomey D., Walsh K., et al. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol 180 (2008) 3797-3806